ArticleDiscover oncology2026
Low GBX2 expression is associated with histological type B thymoma: a multi-omics analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo explore new diagnostic markers and therapeutic targets associated with the histological types of thymoma.
methodsThe TCGA and GEO was used to gather genomic and clinical data from thymoma patients. WGCNA, ConsensusClusterPlus, five machine learning algorithms employed to screen critical histological predictive genes. The effects of different GBX2 expression levels on histological type differences, genomic instability, immune infiltration, carcinogenesis pathway correlation, singel cell expression and other functions in thymoma were examined. Autodock is used to calculate the binding site between GBX2 and potential drugs.
resultsThymoma patients with low GBX2 expression likely have Type 2(B1/B2/B3) thymoma. The mutation rate of GTF2I was lower in samples with low GBX2 expression. GBX2 has a higher degree of methylation in the GTF2I SNV mutation group. GBX2 expression was correlated with microRNA in C19MC cluster and the development of an immunosuppressive tumor microenvironment. GBX2 may influences oxidative phosphorylation pathway activation in thymoma and is expressed on cTEC, mTEC, etc. Erlotinib may be effective in the treatment of thymoma through GBX2.
conclusionLow expression of GBX2 is associated with the formation of Type 2 thymoma by influencing the oxidative phosphorylation pathway in and may participate in immunosuppression in tumor cells. Erlotinib may be a therapeutic drug for thymoma acts through GBX2. These findings suggest that GBX2 may be a potential therapeutic target for clinical thymoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.